

Janet T. Mills  
Governor

Jeanne M. Lambrew, Ph.D.  
Commissioner



Maine Department of Health and Human Services  
Maine Center for Disease Control and Prevention  
11 State House Station  
286 Water Street  
Augusta, Maine 04333-0011  
Tel; (207) 287-8016; Fax (207) 287-9058  
TTY: Dial 711 (Maine Relay)

To: Maine Immunization Program Providers  
From: Maine Immunization Program  
Subject: Meningococcal B Vaccine Campaign  
Date: April 22, 2020

Although we are experiencing unprecedented times with the current COVID-19 pandemic, we cannot lose sight of keeping Mainers safe against other dangerous vaccine preventable diseases. The Maine Immunization Program is kicking off an online Meningococcal B Campaign to increase Meningococcal B immunization rates across the State of Maine.

The Meningitis B Action Project has graciously co-branded materials with our logo for your use within your practice. We strongly encourage you to utilize these materials in educating your patients on a vaccine that they may not otherwise know existed. As healthcare professionals, it is our job to ensure that all children in Maine are offered the best protection against vaccine preventable diseases! To learn more about the powerful story behind the foundation of the Meningitis B Action Project, please visit their website at: <https://meningitisbactionproject.org/>.

The Meningococcal B vaccine is recommended to be given to adolescents and young adults between 16 and 23 years old (**16 – 18 years only when using state supplied vaccine**). There are two brands of the Meningococcal B vaccine, including Bexsero<sup>®</sup> and Trumenba<sup>®</sup>.

**Bexsero<sup>®</sup>**: Clinicians should administer as a 2-dose series to all people 16 through 23 years old (**16-18 years only when using state supplied vaccine**). The vaccine should be administered at 0 and 1 month.

**Trumenba<sup>®</sup>**: Clinicians should administer as a 2-dose series to all people 16 through 23 years old (**16-18 years only when using state supplied vaccine**). The vaccine should be administered at 0 and 6 months. If the second dose is given at an interval of less than 6 months, a third dose should be given at least 4 months after the 2nd dose.

Both brands of vaccine are recommended to also be given as a 2-dose series to people 10 years or older at increased risk of meningococcal disease, including:

- People age 10 years and older who have functional or anatomic asplenia.
- People age 10 years and older who have persistent complement component deficiency, including people with eculizumab (Soliris) or ravulizumab-cwvz (Ultomiris).
- People age 10 years and older who are at risk during an outbreak caused by a vaccine serogroup, such as college campuses.
- Microbiologists who work with meningococcus bacteria in a laboratory

Our goal is to have clinicians vaccinate before patients graduate from high school. An easy way to do this is to:

- Administer the first Meningococcal ACWY at age 11-12.
- Boost with Meningococcal ACWY as early as age 16 years and give the first dose of Meningococcal B at the same visit.
- Administer the remaining Meningococcal B vaccine doses as directed.

If you have additional questions, please contact us at (207) 287-3746.

Thank you for all that you do for the Maine Immunization Program and the children of Maine.